Mesoblast Statistics
Total Valuation
Mesoblast has a market cap or net worth of $1.66 billion. The enterprise value is $1.62 billion.
Important Dates
The last earnings date was Thursday, August 28, 2025, after market close.
Earnings Date | Aug 28, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Mesoblast has 1.28 billion shares outstanding. The number of shares has increased by 22.41% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.28B |
Shares Change (YoY) | +22.41% |
Shares Change (QoQ) | +11.47% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 787.00M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 96.36 |
Forward PS | n/a |
PB Ratio | 2.77 |
P/TBV Ratio | 64.70 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 94.44 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.21.
Current Ratio | 1.99 |
Quick Ratio | 1.72 |
Debt / Equity | 0.21 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -2.87 |
Financial Efficiency
Return on equity (ROE) is -18.95% and return on invested capital (ROIC) is -5.89%.
Return on Equity (ROE) | -18.95% |
Return on Assets (ROA) | -5.37% |
Return on Invested Capital (ROIC) | -5.89% |
Return on Capital Employed (ROCE) | -9.16% |
Revenue Per Employee | $235,589 |
Profits Per Employee | -$1.40M |
Employee Count | 73 |
Asset Turnover | 0.02 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Mesoblast has paid $330,000 in taxes.
Income Tax | 330,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +94.53% in the last 52 weeks. The beta is 1.32, so Mesoblast's price volatility has been higher than the market average.
Beta (5Y) | 1.32 |
52-Week Price Change | +94.53% |
50-Day Moving Average | 13.94 |
200-Day Moving Average | 13.74 |
Relative Strength Index (RSI) | 40.95 |
Average Volume (20 Days) | 188,793 |
Short Selling Information
Short Interest | 2.38M |
Short Previous Month | 2.38M |
Short % of Shares Out | 2.35% |
Short % of Float | n/a |
Short Ratio (days to cover) | 8.87 |
Income Statement
In the last 12 months, Mesoblast had revenue of $17.20 million and -$102.14 million in losses. Loss per share was -$0.08.
Revenue | 17.20M |
Gross Profit | -22.74M |
Operating Income | -62.44M |
Pretax Income | -73.25M |
Net Income | -102.14M |
EBITDA | -58.18M |
EBIT | -62.44M |
Loss Per Share | -$0.08 |
Full Income Statement Balance Sheet
The company has $161.55 million in cash and $128.16 million in debt, giving a net cash position of $33.39 million or $0.03 per share.
Cash & Cash Equivalents | 161.55M |
Total Debt | 128.16M |
Net Cash | 33.39M |
Net Cash Per Share | $0.03 |
Equity (Book Value) | 597.44M |
Book Value Per Share | 0.47 |
Working Capital | 101.72M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$49.95 million and capital expenditures -$680,000, giving a free cash flow of -$50.63 million.
Operating Cash Flow | -49.95M |
Capital Expenditures | -680,000 |
Free Cash Flow | -50.63M |
FCF Per Share | -$0.04 |
Full Cash Flow Statement Margins
Gross Margin | -132.22% |
Operating Margin | -363.08% |
Pretax Margin | -592.00% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Mesoblast does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -22.41% |
Shareholder Yield | -22.41% |
Earnings Yield | -6.16% |
FCF Yield | -3.06% |
Analyst Forecast
The average price target for Mesoblast is $18.00, which is 33.14% higher than the current price. The consensus rating is "Buy".
Price Target | $18.00 |
Price Target Difference | 33.14% |
Analyst Consensus | Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | 126.79% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on January 10, 2024. It was a reverse split with a ratio of 1:2.
Last Split Date | Jan 10, 2024 |
Split Type | Reverse |
Split Ratio | 1:2 |
Scores
Mesoblast has an Altman Z-Score of 2.45 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.45 |
Piotroski F-Score | 5 |